TY - JOUR
T1 - Parenthood in Survivors of Hodgkin Lymphoma: An EORTC-GELA General Population Case-Control Study
AU - van der Kaaij, MAE
AU - Heutte, N
AU - Meijnders, P
AU - Abeilard-Lemoisson, E
AU - Spina, M
AU - Moser, LC
AU - Allgeier, A
AU - Meulemans, B
AU - Dubois, B
AU - Simons, AHM
AU - Lugtenburg, Elly
AU - Aleman, BMP
AU - Noordijk, EM
AU - Ferme, C
AU - Thomas, J
AU - Stamatoullas, A
AU - Fruchart, C
AU - Brice, P
AU - Gaillard, I
AU - Doorduijn, Jeanette
AU - Sebban, C
AU - Smit, WGJM
AU - Bologna, S
AU - Roesink, JM
AU - Ong, F
AU - Andre, MPE
AU - Raemaekers, JMM
AU - Henry-Amar, M
AU - Kluin-Nelemans, HC
PY - 2012
Y1 - 2012
N2 - Purpose We investigated the impact of Hodgkin lymphoma (HL) on parenthood, including factors influencing parenthood probability, by comparing long-term HL survivors with matched general population controls. Patients and Methods A Life Situation Questionnaire was sent to 3,604 survivors treated from 1964 to 2004 in successive clinical trials. Responders were matched with controls (1: 3 or 4) for sex, country, education, and year of birth (10-year groups). Controls were given an artificial date of start of treatment equal to that of their matched case. The main end point was presence of biologic children after treatment, which was evaluated by using conditional logistic regression analysis. Logistic regression analysis w Results In all, 1,654 French and Dutch survivors were matched with 6,414 controls. Median follow-up was 14 years (range, 5 to 44 years). After treatment, the odds ratio (OR) for having children was 0.77 (95% CI, 0.68 to 0.87; P < .001) for survivors compared with controls. Of 898 survivors who were childless before treatment, 46.7% achieved post-treatment parenthood compared with 49.3% of 3,196 childless controls (OR, 0.87; P = .08). Among 756 survivors with children before treatment, 12.4% became paren Conclusion Survivors of HL had slightly but significantly fewer children after treatment than matched general population controls. The difference concerned only survivors who had children before treatment and appears to have more personal than biologic reasons. The chance of successful post-treatment parenthood was 76%. J Clin Oncol 30: 3854-3863. (C) 2012 by American Society of Clinical Oncology
AB - Purpose We investigated the impact of Hodgkin lymphoma (HL) on parenthood, including factors influencing parenthood probability, by comparing long-term HL survivors with matched general population controls. Patients and Methods A Life Situation Questionnaire was sent to 3,604 survivors treated from 1964 to 2004 in successive clinical trials. Responders were matched with controls (1: 3 or 4) for sex, country, education, and year of birth (10-year groups). Controls were given an artificial date of start of treatment equal to that of their matched case. The main end point was presence of biologic children after treatment, which was evaluated by using conditional logistic regression analysis. Logistic regression analysis w Results In all, 1,654 French and Dutch survivors were matched with 6,414 controls. Median follow-up was 14 years (range, 5 to 44 years). After treatment, the odds ratio (OR) for having children was 0.77 (95% CI, 0.68 to 0.87; P < .001) for survivors compared with controls. Of 898 survivors who were childless before treatment, 46.7% achieved post-treatment parenthood compared with 49.3% of 3,196 childless controls (OR, 0.87; P = .08). Among 756 survivors with children before treatment, 12.4% became paren Conclusion Survivors of HL had slightly but significantly fewer children after treatment than matched general population controls. The difference concerned only survivors who had children before treatment and appears to have more personal than biologic reasons. The chance of successful post-treatment parenthood was 76%. J Clin Oncol 30: 3854-3863. (C) 2012 by American Society of Clinical Oncology
U2 - 10.1200/JCO.2011.40.8906
DO - 10.1200/JCO.2011.40.8906
M3 - Article
C2 - 23008303
SN - 0732-183X
VL - 30
SP - 3854
EP - 3863
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 31
ER -